The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Evaluating the effects of the OPERA trial in clinical practice
KRAS mutations are present in 90% of pancreatic ductal adenocarcinomas (PDACs). P.G12C accounts for 1-2% of these KRAS mutations. John H. Strickler, MD, Duke Cancer Institute, Durham, NC, provides an overview of the international, single-arm, Phase I/II trial, CodeBreak100 (NCT03600883) exploring the KRAS p.G12C inhibitor, sotorasib, in patients with previously treated pancreatic cancer harboring the KRAS p.G12C mutation. The primary endpoint is confirmed objective response rate (ORR) and secondary endpoints include duration of response (DoR), progression-free survival (PFS) and overall-survival (OS). 38 patients with pancreatic cancer received sotorasib once daily. ORR was 21.1% and DCR was 84.2%, with a PFS of 4 months and median DoR of 6 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
